- Home
- AENT vs NMRA Comparison
AENT vs NMRA Comparison
Compare AENT & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AENT
- NMRA
- Stock Information
- Founded
- AENT 1990
- NMRA 2019
- Country
- AENT United States
- NMRA United States
- Employees
- AENT N/A
- NMRA N/A
- Industry
- AENT Durable Goods
- NMRA
- Sector
- AENT Consumer Discretionary
- NMRA
- Exchange
- AENT Nasdaq
- NMRA Nasdaq
- Market Cap
- AENT 254.3M
- NMRA 268.5M
- IPO Year
- AENT N/A
- NMRA 2023
- Fundamental
- Price
- AENT $6.99
- NMRA $1.52
- Analyst Decision
- AENT Strong Buy
- NMRA Hold
- Analyst Count
- AENT 1
- NMRA 8
- Target Price
- AENT $10.00
- NMRA $5.83
- AVG Volume (30 Days)
- AENT 84.9K
- NMRA 376.8K
- Earning Date
- AENT 09-10-2025
- NMRA 11-11-2025
- Dividend Yield
- AENT N/A
- NMRA N/A
- EPS Growth
- AENT 228.78
- NMRA N/A
- EPS
- AENT 0.30
- NMRA N/A
- Revenue
- AENT $1,063,457,000.00
- NMRA N/A
- Revenue This Year
- AENT $4.85
- NMRA N/A
- Revenue Next Year
- AENT N/A
- NMRA N/A
- P/E Ratio
- AENT $23.45
- NMRA N/A
- Revenue Growth
- AENT N/A
- NMRA N/A
- 52 Week Low
- AENT $2.04
- NMRA $0.61
- 52 Week High
- AENT $11.57
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- AENT 61.56
- NMRA 41.69
- Support Level
- AENT $6.57
- NMRA $1.42
- Resistance Level
- AENT $7.54
- NMRA $1.59
- Average True Range (ATR)
- AENT 0.71
- NMRA 0.10
- MACD
- AENT 0.10
- NMRA -0.03
- Stochastic Oscillator
- AENT 79.43
- NMRA 19.76
About AENT Alliance Entertainment Holding Corporation
Alliance Entertainment Holding Corp is a top-tier distributor of music, movies, and consumer electronics. It offers products consisting of vinyl records, compact discs, DVDs, Blu-rays, and video games. The company serves customers of every size, providing a suite of services to resellers and retailers around the world.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.